retatrutide triple agonist clinical trial Eli Lilly and Company's agonist, retatrutide, successful in two additional phase 3 obesity trials, delivering significant improvements in weight and A1C Lilly's 'triple G' agonist triumphs

Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation

Seek urgent medical assistance if you develop: severe and persistent abdominal pain repeated vomiting or inability to keep fluids down swelling of the face, lips, tongue or throat difficulty breathing severe dizziness, confusion or fainting sudden loss or rapid deterioration of vision symptoms of severe low blood sugar when using insulin or a sulphonylurea Suspected adverse reactions can also be reported through the MHRA Yellow Card scheme

Counterfeit injector pens have been found to contain everything from normal saline to insulin and other dangerous substances

Dzierzbicka, In vitro studies of antimicrobial activity of Gly-His-Lys conjugates as potential and promising candidates for therapeutics in skin and tissue infections, Bioorg